Browse studies

Find your next paid study

1 recruiting study matching your filters

Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (…

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NYU Langone HealthNCT05815173